"Verdiperstat Fails to Differentiate From Placebo in Critical HEALEY ALS Platform Trial," published by NeurologyLive
Verdiperstat, Biohaven’s investigational first-in-class potent, selective, brain-penetrant, irreversible myeloperoxidase (MPO) enzyme inhibitor, failed to statistically differentiate from placebo in newly announced findings from the pivotal HEALEY ALS Platform Trial.